Drug intelligence / Profile preview

CH1701

Development stage: Phase 2
Lead developer: Vietlife Healthcare
Modality: Small Molecules
Administration: Topical

Overview

CH1701 is a small molecule drug developed by Vietlife Healthcare Corporation, currently in clinical development for the prevention and treatment of radiation therapy burns (radiodermatitis), as well as being investigated for use in breast cancer and burns. The precise mechanism of action of CH1701 has not been disclosed or remains unknown. Clinical trials have reached Phase 2 in Vietnam, focusing on its efficacy and safety for managing skin damage caused by radiation therapy[3][5][1]. No information is available regarding its molecular target, pharmacological class, or detailed modality.

Beyond the preview

Go deeper on CH1701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CH1701.

Explore the full profile